Eli Lilly

News

Novo Nordisk taps brakes on Wegovy as demand soars

Novo Nordisk has said it will temporarily reduce production of the lower starting doses of its weight-loss drug Wegovy, as demand for the therapy continues to challenge it

News

Five takeaways from the new donanemab data

Headlines about the results of TRAILBLAZER-ALZ2 trial of Eli Lilly’s Alzheimer’s drug candidate donanemab are spreading around the world, with some going as far as to sugg

News

Donanemab data “strongest yet” in Alzheimer’s

Eli Lilly has reported the results of its much-anticipated phase 3 trial of amyloid-targeting Alzheimer’s disease therapy donanemab, saying that almost half the patients t

News

Lilly trumpets new weight-loss data with Mounjaro

Eli Lilly’s new therapy Mounjaro has aced a second phase 3 trial as a treatment of obesity or being overweight, this time in patients with type 2 diabetes.

News

Lilly goes toe-to-toe with Novo Nordisk on obesity

Eli Lilly has raised the stakes in its looming battle with Novo Nordisk in the market for obesity drugs, planning a clinical trial that will directly compare its new thera

News

FDA won’t approve Lilly’s mirikizumab for ulcerative colitis

The FDA has issued a complete response letter to Eli Lilly, turning down its attempt to get approval for anti-IL-23p19 antibody mirikizumab as a treatment for ulcerative c

Novo Nordisk taps brakes on Wegovy as demand soars

Five takeaways from the new donanemab data

Donanemab data “strongest yet” in Alzheimer’s

Lilly trumpets new weight-loss data with Mounjaro

Lilly goes toe-to-toe with Novo Nordisk on obesity

FDA won’t approve Lilly’s mirikizumab for ulcerative colitis

Ambrosia's sweet $100m round, and other biofinancings

Using AI-driven synthetic personas to take your insights fur...

Eli Lilly

Editor's Picks